|
Volumn 21, Issue 13-14, 2003, Pages 1310-1316
|
Combined hepatitis B vaccines
|
Author keywords
[No Author keywords available]
|
Indexed keywords
DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE;
HEPATITIS B VACCINE;
PERTUSSIS VACCINE;
POLIOMYELITIS VACCINE;
VIRUS ANTIGEN;
ARTICLE;
COST BENEFIT ANALYSIS;
DIPHTHERIA;
DRUG APPROVAL;
DRUG FORMULATION;
DRUG INDUSTRY;
DRUG SAFETY;
EUROPE;
HAEMOPHILUS INFLUENZAE TYPE B;
HEPATITIS B;
HUMAN;
IMMUNIZATION;
IMMUNOGENICITY;
LAW;
LICENSING;
PERTUSSIS;
POLIOMYELITIS VIRUS;
PREVENTIVE HEALTH SERVICE;
PRIORITY JOURNAL;
PUBLIC HEALTH SERVICE;
TETANUS;
VACCINE PRODUCTION;
CLINICAL TRIALS;
DRUG AND NARCOTIC CONTROL;
HEPATITIS B VACCINES;
HUMANS;
IMMUNIZATION SCHEDULE;
LICENSURE;
VACCINES, COMBINED;
|
EID: 0037471388
PISSN: 0264410X
EISSN: None
Source Type: Journal
DOI: 10.1016/S0264-410X(02)00636-9 Document Type: Article |
Times cited : (15)
|
References (8)
|